RECOMBINANT ADENOVIRUS COMPRISING TISSUE-SPECIFIC PROMOTER AND TUMOR-TARGETING TRANS-SPLICING RIBOZYME AND USES THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 20, 2011
app pub date -
Aug 27, 2008
filing date -
Aug 25, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed herein are a recombinant adenovirus comprising tissue-specific promoters and trans-splicing ribozymes targeting tumor-specific genes, and uses thereof. More specifically, disclosed herein are a recombinant adenovirus comprising (1) a tissue-specific promoter, (2) a trans-splicing ribozyme acting on tumor-specific genes operably linked to the promoter, and (3) a therapeutic or reporter gene linked to 3′ exon of the ribozyme, an anticancer pharmaceutical composition comprising the same, and a composition for cancer diagnosis comprising the same.The recombinant adenovirus exhibits high specificity and significantly improved therapeutic efficacy to gene targeted tissues. Accordingly, the recombinant adenovirus is useful as a gene delivery vector for anticancer agents or cancer diagnostics.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully